Karyopharm Therapeutics Inc (KPTI)
0.814
-0.02
(-2.78%)
USD |
NASDAQ |
Nov 15, 16:00
0.82
+0.01
(+0.74%)
Pre-Market: 08:46
Karyopharm Therapeutics Enterprise Value: 159.07M for Nov. 15, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 15, 2024 | 159.07M |
| November 14, 2024 | 161.99M |
| November 13, 2024 | 165.61M |
| November 12, 2024 | 169.57M |
| November 11, 2024 | 172.58M |
| November 08, 2024 | 166.94M |
| November 07, 2024 | 167.62M |
| November 06, 2024 | 168.17M |
| November 05, 2024 | 163.04M |
| November 04, 2024 | 173.98M |
| November 01, 2024 | 170.25M |
| October 31, 2024 | 181.10M |
| October 30, 2024 | 162.35M |
| October 29, 2024 | 163.26M |
| October 28, 2024 | 169.84M |
| October 25, 2024 | 160.70M |
| October 24, 2024 | 159.31M |
| October 23, 2024 | 163.36M |
| October 22, 2024 | 163.69M |
| October 21, 2024 | 164.12M |
| October 18, 2024 | 166.09M |
| October 17, 2024 | 164.07M |
| October 16, 2024 | 163.32M |
| October 15, 2024 | 161.97M |
| October 14, 2024 | 163.57M |
| Date | Value |
|---|---|
| October 11, 2024 | 164.98M |
| October 10, 2024 | 163.20M |
| October 09, 2024 | 164.15M |
| October 08, 2024 | 162.70M |
| October 07, 2024 | 166.08M |
| October 04, 2024 | 168.26M |
| October 03, 2024 | 167.46M |
| October 02, 2024 | 167.82M |
| October 01, 2024 | 151.97M |
| September 30, 2024 | 161.07M |
| September 27, 2024 | 129.27M |
| September 26, 2024 | 127.10M |
| September 25, 2024 | 125.91M |
| September 24, 2024 | 126.70M |
| September 23, 2024 | 126.04M |
| September 20, 2024 | 131.02M |
| September 19, 2024 | 131.16M |
| September 18, 2024 | 130.84M |
| September 17, 2024 | 132.56M |
| September 16, 2024 | 134.44M |
| September 13, 2024 | 134.28M |
| September 12, 2024 | 130.75M |
| September 11, 2024 | 130.69M |
| September 10, 2024 | 129.39M |
| September 09, 2024 | 130.69M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
39.79M
Minimum
Nov 29 2023
1.668B
Maximum
Mar 06 2020
512.36M
Average
415.39M
Median
Jul 06 2022
Enterprise Value Benchmarks
| Bruker Corp | 9.962B |
| Ionis Pharmaceuticals Inc | 4.217B |
| Apellis Pharmaceuticals Inc | 3.323B |
| NovaBay Pharmaceuticals Inc | 2.764M |
| Palatin Technologies Inc | 8.735M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -32.07M |
| Revenue (Quarterly) | 38.78M |
| Total Expenses (Quarterly) | 65.07M |
| EPS Diluted (Quarterly) | -0.26 |
| Gross Profit Margin (Quarterly) | 96.65% |
| Profit Margin (Quarterly) | -82.70% |
| Earnings Yield | -140.0% |
| Normalized Earnings Yield | -175.51 |